HUMAN ANTIBODIES THAT BIND HUMAN IL-12 AND METHODS FOR PRODUCING

Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an a...

Full description

Saved in:
Bibliographic Details
Main Authors VENTURINI AMY, KAYMAKCALAN ZEHRA, VELDMAN GEERTRUIDA M, WIDOM ANGELA, WHITE MICHAEL, SMITH STEPHEN, SAKORAFAS PAUL, MYLES ANGELA, DUNCAN ALEXANDER ROBERT, FRIEDRICH STUART, ROGUSKA MICHAEL, SALFELD JOCHEN, PASKIND MICHAEL, LABKOVSKY BORIS, ELVIN JOHN GAWAIN, BANERJEE SUBHASHIS, WARNE NICHOLAS W, DERBYSHIRE ELAINE JOY, CARMEN SARA, HOLTET THOR LAS, DU FOU SARAH LEILA, TRACEY DANIEL
Format Patent
LanguageEnglish
Published 23.08.2012
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
Bibliography:Application Number: US201213418049